logo
logo

Epibiologics Appoints Ann Lee-Karlon As Chief Executive Officer And President, Extends Series A Financing To Over $70 Million

Jul 20, 2023about 2 years ago

Round Type

series a

San MateoBiotechnology

Investors

GvVivo CapitalPolaris PartnersMubadala CapitalCodon CapitalTaiho VenturesDigitalis Ventures

Description

EpiBiologics, a biotechnology company advancing a next-generation antibody-based protein degradation platform and pipeline for membrane and extracellular drug targets, announced today that Ann Lee-Karlon, Ph.D., will join as Chief Executive Officer, President, and member of the Board of Directors. Dr. Lee-Karlon will focus on expanding EpiBiologics’ proprietary EpiTAC platform, establishing value-driven collaborations, and building the company’s pipeline of bispecific antibody protein degrader therapeutics.

Company Information

Company

EpiBiologics

Location

1900 Alameda de las Pulgas

San Mateo, California, United States

About

EpiBiologics is building a next-generation protein degradation platform that targets membrane and extracellular proteins. EpiBiologics was founded in 2022 based on the pioneering work from academic founder Dr. Jim Wells of the University of California San Francisco (UCSF). The Company’s proprietary EpiTAC platform is a modular antibody-based system that enables the precise degradation of disease-driving membrane and extracellular proteins in a tissue-specific manner. Headquartered in San Mateo, EpiBiologics is backed by leading healthcare investors and aims to develop first-in-class and best-in-class targeted therapies across multiple therapeutic areas.

Related People

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers